Century Therapeutics, Inc. Payments to Acquire Additional Interest in Subsidiaries
Century Therapeutics, Inc. (IPSC) reported Payments to Acquire Additional Interest in Subsidiaries of $9.61 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries · last filed 2026-03-12
- Century Therapeutics, Inc. payments to acquire additional interest in subsidiaries for the quarter ending 2024-12-31 was $0.00.
- Century Therapeutics, Inc. payments to acquire additional interest in subsidiaries for the quarter ending 2024-09-30 was $0.00.
- Century Therapeutics, Inc. payments to acquire additional interest in subsidiaries for fiscal 2024 was $9.61M.
| Period end | Payments to Acquire Additional Interest in Subsidiaries 3 month | Payments to Acquire Additional Interest in Subsidiaries 6 month | Payments to Acquire Additional Interest in Subsidiaries 9 month | Payments to Acquire Additional Interest in Subsidiaries 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $9.61M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $9.61M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $9.61M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |